T4E - it seems to me that most AIM companies are start-ups which haven't made any money and may or will not do so for a long time! So what do you think their share prices will achieve until they actually start delivering on their IP? The trick is not to be heavily invested in such companies early on. I only dabble in this share game because of the risks. |
I have already lost over 90%. that is why I am trying to save other investors from this fraud company. It is a normal pattern for the last 5 years to raise money and destroy share holder value. V.lad has delivered nothing for share holders. they are running this company for their own salaries only. |
T4E - so you're a satisfied LTH then? :o) |
V. LAD is a deceiver, he has been doing this for many many years to pay himself and his corrupts team huge salaries, he has not delivered anything for the share holders until now apart from raising cash and ripping shareholders. That is why he did share consolidation now he will bring it back to penny share again. This is the worst company you could ever invest your money. This is a scam company completely run by deceivers and Liars. New investors should stay away from this fraud company unless you want to loose your hard earned money. |
No mate the II will dump them in the gerbils. There's special transparency rules for scumbag brokers. |
That said clearly the II will been disclosing their holding via a TR1 given they've taken nearly 10 percent of the enlarged share capital. |
That was one huge discount and not for all that much dosh either.I'm guessing the shares will settle around the 1.80 issue price - why raise such a small amount at that level of discount? |
JakNife - yes, that was my point - hence my LOL at the end. :o) |
I feel better warning about the gerbil baiters and not like the boiler room crews trying to suck people into these lifestyle scams. |
soldi,
"JakNife - OK, I'll await mid April and then massively top-up at 120p LOL."
Why not wait until May and top up at 90p?
Or June and top up at 70p?
Or July ...
August ...
Sept ...
JakNife |
JakNife - OK, I'll await mid April and then massively top-up at 120p LOL. |
Have you nothing better in life to do, just trolling boards all day.such a sad low life.Anything red and your like a magpie to share your doom and gloom.We've not seen you over at MOS for awhile is it because it's on a BIG up ATM. |
yep, unbelievable |
8 January £340,000 @ 340p (+warrants@500p)19 February £285,000 @ 300p (+warrants@400p)11 March £709,200 @ 180p (+warrants@350p)
^^ The pattern is glaringly obvious!
I await a fund raise of c. £600k in mid April at 120p!
Anyone who thinks that this drip drip dilution is positive for shareholders is deluded!
JakNife |
Like how the way VLAD has convinced that it was the institution who came crying to hemo 180p ouch |
That is an eye watering discount of 40 percent for well under a million pound raise.Quite staggering. |
printing at £1.80 |
Roll out the confetti machine AGAIN |
Appreciate data W, but for me, 2017 etc,, history? slam dunk short! |
Tell me you don't know anything about medical research without saying that you don't know anything about medical research, don't worry, you just did |
This company has never delivered anything for share holders until now. It was created only to serve and pay salaries to the corrupt and incompetent management. |
 Written by:
Stephen Gunnion
PROACTIVE
Hemogenyx Pharmaceuticals PLC
(LSE:HEMOOTC:HOPHF)
Hemogenyx Pharmaceuticals marks major milestone with first patient dosing
Published: 08:00 27 Feb 2025 GMT
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler talked with Proactive's Stephen Gunnion about the company’s recent milestone—the first human dose of its proprietary CAR-T cell therapy, HG-CT-1, for treating relapsed refractory acute myeloid leukemia (AML) in adults. This is a significant development in tackling one of the deadliest blood cancers, which has a low remission rate with current frontline therapies.
Sandler explained, “We are trying to cure a very deadly disease which is called acute myeloid leukemia... This is one of the worst blood cancers in existence.” He highlighted that only 30% of newly diagnosed patients respond to frontline therapies, leaving a significant need for more effective treatments.
The therapy uses third-generation chimeric antigen receptor (CAR) technology, which, according to Sandler, offers the same efficacy as the current second-generation CARs but with enhanced safety. The company is poised to accelerate its clinical trials, pending resource availability, with the potential to infuse patients every 14 days after the fourth patient.
With the first patient showing no adverse effects so far, Hemogenyx is hopeful about the progress of HG-CT-1 and is ready to scale up manufacturing as new patients are identified. |
Not much of a reaction but I guess it will take a positive result to do that.Can see this dropping while we wait |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
